Moleculin Biotech is a clinical-stage pharmaceutical company dedicated to developing oncology drug candidates. Its primary focus is on Annamycin, a next-generation anthracycline in Phase 1/2 trials for treating relapsed or refractory acute myeloid leukemia and lung metastases. The company also develops immune modulators like WP1066 and metabolism inhibitors such as WP1122, targeting various cancers and viruses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.